Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients : A Potential Factor Predisposing to Thrombosis and Its Persistence

Circulation - United States
doi 10.1161/01.cir.97.22.2213
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (From the BARI 2D Trial)

American Journal of Cardiology
Cardiovascular MedicineCardiology
2010English

Thrombin and Plasmin Generation in Patients With Plasminogen or Plasminogen Activator Inhibitor Type 1 Deficiency

Haemophilia
MedicineGeneticsHematology
2019English

Accessibility of Receptor-Bound Urokinase to Type-1 Plasminogen Activator Inhibitor.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1989English

Plasminogen Activator Inhibitor-1 Gene Polymorphism as a Risk Factor for Vascular Complications in Type 2 Diabetes Mellitus

Egyptian Journal of Medical Human Genetics
Genetics
2019English

Prognostic Value of Tissue-Type Plasminogen Activator (tPA) and Its Complex With the Type-1 Inhibitor (PAI-1) in Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1999English

Antidiabetic PPARgamma-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2002English

Human Visceral Adipose Tissue and the Plasminogen Activator Inhibitor Type 1

International Journal of Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2007English

Interaction of Single-Chain Urokinase and Plasminogen Activator Inhibitor Type 1

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1995English

Increased Plasminogen Activator Inhibitor-1, Decreased Tissue Factor Pathway Inhibitor, and Unchanged Thrombin-Activatable Fibrinolysis Inhibitor Levels in Patients With Primary Hyperparathyroidism

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy